Journal Article
. 2014 Aug; 9(8):e104669.
doi: 10.1371/journal.pone.0104669.

Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor

Mikiya Ishihara 1 Naohiro Seo 1 Jun Mitsui 2 Daisuke Muraoka 1 Maki Tanaka 3 Junichi Mineno 3 Hiroaki Ikeda 1 Hiroshi Shiku 1 
Affiliations
  • PMID: 25105508
  •     50 References
  •     7 citations

Abstract

Oncolytic virotherapy combined with immunomodulators is a novel noninvasive strategy for cancer treatment. In this study, we examined the tumoricidal effects of oncolytic HF10, a naturally occurring mutant of herpes simplex virus type-1, combined with an agonistic DTA-1 monoclonal antibody specific for the glucocorticoid-induced tumor necrosis factor receptor. Two murine tumor models were used to evaluate the therapeutic efficacies of HF10 virotherapy combined with DTA-1. The kinetics and immunological mechanisms of DTA-1 in HF10 infection were examined using flow cytometry and immunohistochemistry. Intratumoral administration of HF10 in combination with DTA-1 at a low dose resulted in a more vigorous attenuation of growth of the untreated contralateral as well as the treated tumors than treatment with either HF10 or DTA-1 alone. An accumulation of CD8(+) T cells, including tumor- and herpes simplex virus type-1-specific populations, and a decrease in the number of CD4(+) Foxp3(+) T regulatory cells were seen in both HF10- and DTA-1-treated tumors. Studies using Fc-digested DTA-1 and Fcγ receptor knockout mice demonstrated the direct participation of DTA-1 in regulatory T cell depletion by antibody-dependent cellular cytotoxicity primarily via macrophages. These results indicated the potential therapeutic efficacy of a glucocorticoid-induced tumor necrosis factor receptor-specific monoclonal antibody in oncolytic virotherapy at local tumor sites.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Caroline J Breitbach, James Burke, +22 authors, David H Kirn.
Nature, 2011 Sep 03; 477(7362). PMID: 21886163
Highly Cited.
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, +27 authors, Mario Sznol.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127    Free PMC article.
Highly Cited.
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Anik L Côté, Peisheng Zhang, +5 authors, Mary Jo Turk.
J Immunol, 2010 Nov 26; 186(1). PMID: 21106849    Free PMC article.
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
Dominik Wolf, Anna M Wolf, +7 authors, Christian Marth.
Clin Cancer Res, 2005 Dec 03; 11(23). PMID: 16322292
Highly Cited.
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
Tyler J Curiel, George Coukos, +18 authors, Weiping Zou.
Nat Med, 2004 Aug 24; 10(9). PMID: 15322536
Highly Cited.
Ipilimumab for patients with advanced mucosal melanoma.
Michael A Postow, Jason J Luke, +17 authors, Richard D Carvajal.
Oncologist, 2013 May 30; 18(6). PMID: 23716015    Free PMC article.
Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
Jun Shimizu, Sayuri Yamazaki, +2 authors, Shimon Sakaguchi.
Nat Immunol, 2002 Jan 29; 3(2). PMID: 11812990
Highly Cited.
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, +10 authors, Jedd D Wolchok.
PLoS One, 2010 May 11; 5(5). PMID: 20454651    Free PMC article.
Highly Cited.
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
B L Liu, M Robinson, +9 authors, R S Coffin.
Gene Ther, 2003 Feb 22; 10(4). PMID: 12595888
Highly Cited.
Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer.
A Nakao, H Kimata, +5 authors, Y Nishiyama.
Ann Oncol, 2004 May 21; 15(6). PMID: 15151960
HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.
Isamu Mori, Beixing Liu, +6 authors, Yukihiro Nishiyama.
Microbes Infect, 2005 Aug 02; 7(15). PMID: 16054416
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Antoni Ribas, Richard Kefford, +21 authors, Axel Hauschild.
J Clin Oncol, 2013 Jan 09; 31(5). PMID: 23295794    Free PMC article.
Highly Cited.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.
J H Kim, J Y Oh, +9 authors, T H Hwang.
Mol Ther, 2006 Aug 15; 14(3). PMID: 16905462
Highly Cited.
Oncolytic viruses in cancer therapy.
Markus J V Vähä-Koskela, Jari E Heikkilä, Ari E Hinkkanen.
Cancer Lett, 2007 Mar 27; 254(2). PMID: 17383089    Free PMC article.
Highly Cited. Review.
Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
Daisuke Muraoka, Takuma Kato, +10 authors, Hiroyoshi Nishikawa.
J Immunol, 2010 Aug 25; 185(6). PMID: 20733202
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
Kuibeom Ko, Sayuri Yamazaki, +7 authors, Shimon Sakaguchi.
J Exp Med, 2005 Sep 28; 202(7). PMID: 16186187    Free PMC article.
Highly Cited.
Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.
Ya-Qing Li, Fang-Fang Liu, +3 authors, Li Fu.
PLoS One, 2013 Oct 15; 8(10). PMID: 24124553    Free PMC article.
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.
Hiroyoshi Nishikawa, Takuma Kato, +6 authors, Hiroshi Shiku.
Cancer Res, 2008 Jul 18; 68(14). PMID: 18632650
Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.
Naoko Imai, Hiroaki Ikeda, +5 authors, Hiroshi Shiku.
Cancer Sci, 2009 May 13; 100(7). PMID: 19432889
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.
Howard L Kaufman, Dae Won Kim, +3 authors, Seunghee Kim-Schulze.
Ann Surg Oncol, 2009 Nov 17; 17(3). PMID: 19915919
Highly Cited.
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.
Tae-Ho Hwang, Anne Moon, +11 authors, David H Kirn.
Mol Ther, 2011 Jul 21; 19(10). PMID: 21772252    Free PMC article.
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
Howard L Kaufman, Steven D Bines.
Future Oncol, 2010 Jun 10; 6(6). PMID: 20528232
Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
Jeffrey S Weber, Reinhard Dummer, +3 authors, MDX010-20 Investigators.
Cancer, 2013 Feb 13; 119(9). PMID: 23400564
Highly Cited.
Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2.
Y Nishiyama, H Kimura, T Daikoku.
J Virol, 1991 Aug 01; 65(8). PMID: 1649347    Free PMC article.
Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Fumi Goshima, Shinichi Esaki, +3 authors, Yukihiro Nishiyama.
Int J Cancer, 2013 Nov 23; 134(12). PMID: 24265099
A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.
G Nocentini, L Giunchi, +5 authors, C Riccardi.
Proc Natl Acad Sci U S A, 1997 Jun 10; 94(12). PMID: 9177197    Free PMC article.
Highly Cited.
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Byeong-Ho Park, Taeho Hwang, +16 authors, David H Kirn.
Lancet Oncol, 2008 May 23; 9(6). PMID: 18495536
Highly Cited.
FcR gamma chain deletion results in pleiotrophic effector cell defects.
T Takai, M Li, +2 authors, J V Ravetch.
Cell, 1994 Feb 11; 76(3). PMID: 8313472
Highly Cited.
A new mechanism for tumor induced platelet aggregation. Comparison with mechanisms shared by other tumor with possible pharmacologic strategy toward prevention of metastases.
W A Lerner, E Pearlstein, C Ambrogio, S Karpatkin.
Int J Cancer, 1983 Apr 15; 31(4). PMID: 6299977
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
Hideto Kimata, Tsuneo Imai, +5 authors, Akimasa Nakao.
Ann Surg Oncol, 2006 Jul 26; 13(8). PMID: 16865590
Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
S-I Kohno, C Luo, +5 authors, Y Nishiyama.
Cancer Gene Ther, 2007 Aug 19; 14(11). PMID: 17693992
In vivo ligation of glucocorticoid-induced TNF receptor enhances the T-cell immunity to herpes simplex virus type 1.
Soojin La, Eunhwa Kim, Byungsuk Kwon.
Exp Mol Med, 2005 Jul 08; 37(3). PMID: 16000873
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Adam D Cohen, Adi Diab, +9 authors, Alan N Houghton.
Cancer Res, 2006 May 03; 66(9). PMID: 16651447    Free PMC article.
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.
A Nakao, H Kasuya, +12 authors, Y Nishiyama.
Cancer Gene Ther, 2010 Nov 26; 18(3). PMID: 21102422
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Clinical development directions in oncolytic viral therapy.
R M Eager, J Nemunaitis.
Cancer Gene Ther, 2011 Mar 26; 18(5). PMID: 21436867
Review.
The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.
A Y Huang, P H Gulden, +9 authors, E M Jaffee.
Proc Natl Acad Sci U S A, 1996 Sep 03; 93(18). PMID: 8790399    Free PMC article.
Highly Cited.
JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
Alison E Merrick, Elizabeth J Ilett, Alan A Melcher.
Curr Opin Investig Drugs, 2009 Nov 28; 10(12). PMID: 19943208
Review.
Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate.
Wei Wang, Philip Hodkinson, +4 authors, Tariq Sethi.
Int J Cancer, 2012 Apr 26; 131(6). PMID: 22532287
Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma.
H Ikeda, N Ohta, +5 authors, H Shiku.
Proc Natl Acad Sci U S A, 1997 Jun 10; 94(12). PMID: 9177225    Free PMC article.
Rethinking herpes simplex virus: the way to oncolytic agents.
Gabriella Campadelli-Fiume, Carla De Giovanni, +3 authors, Laura Menotti.
Rev Med Virol, 2011 Jun 01; 21(4). PMID: 21626603
Review.
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.
Loise M Francisco, Victor H Salinas, +4 authors, Arlene H Sharpe.
J Exp Med, 2009 Dec 17; 206(13). PMID: 20008522    Free PMC article.
Highly Cited.
Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
Yasushi Fujimoto, Terukazu Mizuno, +4 authors, Yukihiro Nishiyama.
Acta Otolaryngol, 2006 Aug 23; 126(10). PMID: 16923721
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
Caroline J Breitbach, Tony Reid, +2 authors, David H Kirn.
Cytokine Growth Factor Rev, 2010 May 18; 21(2-3). PMID: 20472490
Review.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
Rebecca S McHugh, Matthew J Whitters, +4 authors, Michael C Byrne.
Immunity, 2002 Mar 01; 16(2). PMID: 11869690
Highly Cited.
Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Jun Mitsui, Hiroyoshi Nishikawa, +9 authors, Hiroshi Shiku.
Clin Cancer Res, 2010 May 13; 16(10). PMID: 20460483
Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.
Biao Wang, Xu Yan, +4 authors, Xin Meng.
Oncotarget, 2015 Apr 25; 6(18). PMID: 25909216    Free PMC article.
In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.
Linda Hammerich, Adam Binder, Joshua D Brody.
Mol Oncol, 2015 Dec 04; 9(10). PMID: 26632446    Free PMC article.
Review.
Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Ding Wei, Qian Li, +9 authors, Huijie Bian.
J Exp Clin Cancer Res, 2015 Dec 23; 34. PMID: 26689432    Free PMC article.
Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
Mee Y Bartee, Katherine M Dunlap, Eric Bartee.
Cancer Res, 2017 Mar 21; 77(11). PMID: 28314785    Free PMC article.
Highly Cited.
Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells.
Naohiro Seo, Yoshitaka Shirakura, +5 authors, Hiroshi Shiku.
Nat Commun, 2018 Feb 01; 9(1). PMID: 29382847    Free PMC article.
Potential of oncolytic viruses in the treatment of multiple myeloma.
Eric Bartee.
Oncolytic Virother, 2018 Mar 06; 7. PMID: 29503813    Free PMC article.
Review.
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Mikiya Ishihara, Yasutaka Tono, +16 authors, Hiroshi Shiku.
Cancer Immunol Immunother, 2020 Jan 26; 69(4). PMID: 31980914    Free PMC article.